Abstract:Accurate prediction of binding between human leukocyte antigen (HLA) class I molecules and antigenic peptide segments is a challenging task and a key bottleneck in personalized immunotherapy for cancer. Although existing prediction tools have demonstrated significant results using established datasets, most can only predict the binding affinity of antigenic peptides to HLA and do not enable the immunogenic interpretation of new antigenic epitopes. This limitation results from the training data for the computational models relying heavily on a large amount of peptide-HLA (pHLA) eluting ligand data, in which most of the candidate epitopes lack immunogenicity. Here, we propose an adaptive immunogenicity prediction model, named MHLAPre, which is trained on the large-scale MS-derived HLA I eluted ligandome (mostly presented by epitopes) that are immunogenic. Allele-specific and pan-allelic prediction models are also provided for endogenous peptide presentation. Using a meta-learning strategy, MHLAPre rapidly assessed HLA class I peptide affinities across the whole pHLA pairs and accurately identified tumor-associated endogenous antigens. During the process of adaptive immune response of T-cells, pHLA-specific binding in the antigen presentation is only a pre-task for CD8+ T-cell recognition. The key factor in activating the immune response is the interaction between pHLA complexes and T-cell receptors (TCRs). Therefore, we performed transfer learning on the pHLA model using the pHLA-TCR dataset. In pHLA binding task, MHLAPre demonstrated significant improvement in identifying neoepitope immunogenicity compared with five state-of-the-art models, proving its effectiveness and robustness. After transfer learning of the pHLA-TCR data, MHLAPre also exhibited relatively superior performance in revealing the mechanism of immunotherapy. MHLAPre is a powerful tool to identify neoepitopes that can interact with TCR and induce immune responses. We believe that the proposed method will greatly contribute to clinical immunotherapy, such as anti-tumor immunity, tumor-specific T-cell engineering, and personalized tumor vaccine.

Predicting HLA class II antigen presentation through integrated deep learning

HLAIImaster: a deep learning method with adaptive domain knowledge predicts HLA II neoepitope immunogenic responses

LRMAHpan: a novel tool for multi-allelic HLA presentation prediction using Resnet-based and LSTM-based neural networks

HLAIIPred: Cross-Attention Mechanism for Modeling the Interaction of HLA Class II Molecules with Peptides

Pan-specific Multi Allelic Phla Presenting Prediction Through Resnet-based and LSTM-based Neural Networks

Deep Learning-Enhanced MHC-II Presentation Prediction and Peptidome Deconvolution

DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity

HLA class I binding prediction via convolutional neural networks

CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II

MATHLA: a robust framework for HLA-peptide binding prediction integrating bidirectional LSTM and multiple head attention mechanism

A novel HLA Class II presentation prediction algorithm deciphers immunogenic CD4 epitopes specific to KRAS G12C

Meta learning for mutant HLA class I epitope immunogenicity prediction to accelerate cancer clinical immunotherapy

Unsupervised and supervised AI on molecular dynamics simulations reveals complex characteristics of HLA-A2-peptide immunogenicity

DeepHLApan: A Deep Learning Approach for High-Confidence Neoantigen Prediction

Improvement of Neoantigen Identification Through Convolution Neural Network

TripHLApan: predicting HLA molecules binding peptides based on triple coding matrix and transfer learning

High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets

DapNet-HLA: Adaptive Dual-Attention Mechanism Network Based on Deep Learning to Predict Non-Classical HLA Binding Sites.

Machine learning application to predict binding affinity between peptide containing non-canonical amino acids and HLA0201

Investigating the human and nonobese diabetic mouse MHC class II immunopeptidome using protein language modeling